EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites

Pratap Vydyam iD, Meenal Chand, Shalev Gihaz, Isaline Renard, Gavin D Heffernan, Laura R Jacobus, David P Jacobus, Kurt W Saionz, Raju Shah, Hong-Ming Shieh, Jacek Terpinski, Wenyi Zhao und 2 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00423-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Pratap Vydyam und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connect…. Hauptthemen laut MEDLINE: Triazines, Babesia, Plasmodium falciparum, Erythrocytes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Babesia and Plasmodium pathogens, the causative agents of babesiosis and malaria, are vector-borne intraerythrocytic protozoan parasites, posing significant threats to both human and animal health. The widespread resistance exhibited by these pathogens to various classes of antiparasitic drugs underscores the need for the development of novel and more effective therapeutic strategies. Antifolates have long been recognized as attractive antiparasitic drugs as they target the folate pathway, which is essential for the biosynthesis of purines and pyrimidines, and thus is vital for the survival and proliferation of protozoan parasites. More efficacious and safer analogs within this class are needed to overcome challenges due to resistance to commonly used antifolates, such as pyrimethamine, and to address liabilities associated with the dihydrotriazines, WR99210 and JPC-2067. Here, we utilized an in vitro culture condition suitable for the continuous propagation of Babesia duncani, Babesia divergens, Babesia MO1, and Plasmodium falciparum in human erythrocytes to screen a library of 50 dihydrotriazines and 29 biguanides for their efficacy in vitro and compared their potency and therapeutic indices across different species and isolates. We identified nine analogs that inhibit the growth of all species, including the P. falciparum pyrimethamine-resistant strain HB3, with IC 50 values below 10 nM, and display excellent in vitro therapeutic indices. These compounds hold substantial promise as lead antifolates for further development as broad-spectrum antiparasitic drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazinesBabesiaPlasmodium falciparumErythrocytesHumansBabesiosisAntimalarialsParasitic Sensitivity TestsFolic Acid Antagonists

Stichwörter der Autor:innen

DHFR-TSantifolatesantiparasitic drugsapicomplexandihydrotriazinenucleotide biosynthesis

Substanzen

TriazinesAntimalarialsFolic Acid Antagonists

Autor:innen und Institutionen

  • Departments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
  • Jacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
  • Institut de Biologie Computationnelle (IBC), and Institut de Recherche en Cancérologie de Montpellier (IRCM - INSERM U1194), Institut régional du Cancer Montpellier (ICM) & Université de Montpellier, Montpellier, France.

ORCID-Profile: Pratap Vydyam, Choukri Ben Mamoun

Förderung

  • NIAID NIH HHS

Zitieren

APA

Vydyam, P., Chand, M., Gihaz, S., Renard, I., Heffernan, G. D., Jacobus, L. R., Jacobus, D. P., Saionz, K. W., Shah, R., Shieh, H. M., Terpinski, J., Zhao, W., Cornillot, E., & Ben Mamoun, C. (2024). In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00423-24

Vancouver

Vydyam P, Chand M, Gihaz S, Renard I, Heffernan GD, Jacobus LR, et al. In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00423-24

BibTeX
@article{Vydyam2024,
  author = {Vydyam, Pratap and Chand, Meenal and Gihaz, Shalev and Renard, Isaline and Heffernan, Gavin D and Jacobus, Laura R and Jacobus, David P and Saionz, Kurt W and Shah, Raju and Shieh, Hong-Ming and Terpinski, Jacek and Zhao, Wenyi and Cornillot, Emmanuel and Ben Mamoun, Choukri},
  title = {In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00423-24}
}
Kostenlos starten →